GO:0047273 galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047273 describes the enzymatic activity that transfers N-acetyl-D-galactosamine from UDP-N-acetyl-D-galactosamine to globotriaosylceramide (Gb3), producing globoside (Gb4) and UDP.
• This activity is a beta-1,3-N-acetylgalactosaminyltransferase step in the globo-series glycosphingolipid biosynthetic pathway.
• The reaction is part of the broader O-GalNAc glycosylation repertoire, which regulates protein stability, trafficking, and signaling.
• Altered O-GalNAc glycosylation, including globo-series glycosphingolipid synthesis, contributes to cancer stemness, metastasis, and immune evasion.
• Enzymes with this activity are studied using CRISPR knockout, point-mutation, knock-in, and overexpression models to dissect substrate specificity and disease relevance.
• GALNT-family enzymes, which share O-GalNAc transfer chemistry, are emerging therapeutic targets in oncology and metabolic disease.
Description
GO:0047273, galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity, is a molecular function defined by the transfer of N-acetyl-D-galactosamine (GalNAc) from UDP-N-acetyl-D-galactosamine to the terminal galactose of globotriaosylceramide (Gb3), yielding globoside (Gb4) and UDP. This reaction is a committed step in the globo-series glycosphingolipid biosynthetic pathway and is catalyzed by beta-1,3-N-acetylgalactosaminyltransferases, often referred to as globoside synthases. The activity is part of the larger family of O-GalNAc glycosylation reactions that modify glycoproteins and glycolipids, influencing cell surface recognition, signaling, and immune interactions. Researchers study GO:0047273 because globo-series glycosphingolipids are implicated in cancer progression, metastasis, and immune regulation. For example, O-GalNAc glycosylation can activate complement and coagulation cascades that drive organotropic metastasis, and GALNT2 sustains glioma stem cells by promoting CD44 expression. In non-small cell lung cancer, GALNT7-dependent ferroptosis suppression contributes to immunotherapy resistance, and GALNT2 acts as an oncogenic driver. These findings highlight the importance of understanding the enzymatic steps that build complex glycosphingolipids. This article integrates the QuickGO definition of GO:0047273 with verified PubMed literature to explain the mechanism, key genes, disease links, and experimental models used to study this activity. It is intended for researchers designing CRISPR-based screens, biochemical assays, or therapeutic strategies targeting glycosphingolipid metabolism.
galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity At A Glance
| GO ID | GO:0047273 |
|---|---|
| GO term | galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | beta3GalNAc-T1; globoside synthase activity; globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase activity; UDP-N-acetylgalactosamine:globotriaosylceramide beta-3-N-acetylgalactosaminyltransferase activity |
| Major function | Transfer of GalNAc from UDP-GalNAc to globotriaosylceramide to form globoside (Gb4) |
| Reaction | UDP-N-acetyl-D-galactosamine + alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide = UDP + beta-N-acetyl-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide |
| Pathway | Globo-series glycosphingolipid biosynthesis |
| Substrate | Globotriaosylceramide (Gb3) and UDP-GalNAc |
| Product | Globoside (Gb4) and UDP |
What Is GO:0047273?
GO:0047273 is defined as the catalysis of the reaction: UDP-N-acetyl-D-galactosamine + alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide = UDP + beta-N-acetyl-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide. In simpler terms, this activity adds a GalNAc sugar to a specific glycolipid (Gb3) to form globoside (Gb4), using UDP-GalNAc as the donor substrate.
Why Is galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity Important in Cell Biology?
GO:0047273 is important because it represents a key enzymatic step in the biosynthesis of globo-series glycosphingolipids, which are critical for cell membrane organization, signal transduction, and immune recognition. Dysregulation of O-GalNAc glycosylation, including globo-series glycolipid synthesis, is linked to cancer stemness, metastasis, and immune evasion. Understanding this activity provides insights into glycosphingolipid biology and offers potential targets for therapeutic intervention in oncology and metabolic disorders.
• Defines a committed step in globo-series glycosphingolipid biosynthesis, producing globoside (Gb4).
• Contributes to the diversity of O-GalNAc glycosylation, which regulates protein stability and signaling.
• Globo-series glycosphingolipids are involved in cancer cell adhesion, migration, and metastasis.
• Altered glycosylation can modulate immune recognition and complement activation.
• Enzymes with this activity are potential biomarkers or therapeutic targets in glioma, lung cancer, and other malignancies.
• Studying this activity helps elucidate mechanisms of immunotherapy resistance.
• CRISPR models enable precise dissection of gene function in glycosphingolipid pathways.
• Biochemical assays for this activity support drug discovery targeting glycosyltransferases.
• Understanding substrate specificity can guide engineering of glycosyltransferases for biotechnology.
• Links glycolipid metabolism to systemic processes such as osteoid mineralization and hypoglycemia counterregulation.
Molecular Mechanism of galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs a specific lipid sugar (Gb3) and a donor sugar (UDP-GalNAc).
The enzyme recognizes globotriaosylceramide (Gb3) as its acceptor substrate and UDP-N-acetyl-D-galactosamine (UDP-GalNAc) as the donor substrate. Binding involves a catalytic domain that positions the terminal galactose of Gb3 for nucleophilic attack on the anomeric carbon of GalNAc. This step is part of the globo-series glycosphingolipid pathway.
Catalytic Transfer of GalNAc
In simple terms: The enzyme moves the GalNAc sugar from UDP to Gb3, making Gb4.
The catalytic mechanism involves the transfer of N-acetyl-D-galactosamine from UDP-GalNAc to the alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide acceptor, forming beta-N-acetyl-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide (globoside, Gb4) and UDP. This beta-1,3-linkage is characteristic of globoside synthase activity.
Role of Divalent Cations and Cofactors
In simple terms: Some glycosyltransferases need metal ions to work, but this one may not.
Many glycosyltransferases require divalent metal ions such as Mn2+ for activity, but the specific cofactor requirements for GO:0047273 are not detailed in the QuickGO definition. Researchers should refer to biochemical studies for precise cofactor dependencies.
Regulation of Enzyme Activity
In simple terms: The enzyme's activity can be turned up or down by cellular signals.
The activity of glycosyltransferases can be regulated at multiple levels, including gene expression, post-translational modifications, and substrate availability. For example, GALNT2, an O-GalNAc transferase, is regulated in cancer and metabolic contexts. However, specific regulatory mechanisms for GO:0047273 remain to be fully elucidated.
Integration with Glycosphingolipid Metabolism
In simple terms: This enzyme works as part of a larger assembly line that builds complex lipids.
GO:0047273 functions within the globo-series glycosphingolipid biosynthetic pathway, where sequential glycosylation steps convert lactosylceramide to Gb3, then to Gb4, and further to globopentaosylceramide and other derivatives. This pathway intersects with O-GalNAc glycosylation networks that modify proteins and lipids.
Key Genes Involved in GO:0047273 galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity
The following genes encode enzymes or regulators associated with O-GalNAc glycosylation and related glycosphingolipid pathways, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALNT1 | O-GalNAc transferase initiating mucin-type O-glycosylation | Model for studying glycosylation in cancer and signaling |
| GALNT2 | O-GalNAc transferase; oncogenic driver in lung cancer; sustains glioma stem cells | Target for cancer therapy and metabolic regulation |
| GALNT3 | O-GalNAc transferase; regulates FGF23 stability and osteoid mineralization | Model for bone mineralization and phosphate homeostasis |
| GALNT7 | O-GalNAc transferase; suppresses ferroptosis in NSCLC | Target for overcoming immunotherapy resistance |
| GALNT10 | O-GalNAc transferase | Potential role in glycosylation-dependent processes |
| GALNT14 | O-GalNAc transferase | Candidate for cancer biomarker studies |
| B3GALNT1 | Beta-1,3-N-acetylgalactosaminyltransferase; globoside synthase | Direct enzyme for GO:0047273; model for glycolipid biosynthesis |
| B3GALNT2 | Beta-1,3-N-acetylgalactosaminyltransferase | Related enzyme in glycosphingolipid synthesis |
| A4GALT | Alpha-1,4-galactosyltransferase; synthesizes Gb3 | Upstream of GO:0047273 in globo-series pathway |
| GBGT1 | Globoside alpha-1,3-N-acetylgalactosaminyltransferase | Modifies globoside; related to blood group antigens |
| FUT1 | Fucosyltransferase | Competes with globo-series pathways |
| FUT2 | Fucosyltransferase | Modulates glycosphingolipid antigens |
| ST3GAL5 | Sialyltransferase | Competes for lactosylceramide substrate |
| UGCG | Glucosylceramide synthase | First step in glycosphingolipid synthesis |
| B4GALT5 | Beta-1,4-galactosyltransferase | Synthesizes lactosylceramide, precursor to Gb3 |
| B4GALT6 | Beta-1,4-galactosyltransferase | Isoform involved in glycolipid synthesis |
| HEXA | Beta-hexosaminidase A | Degrades globoside; lysosomal storage disease model |
| HEXB | Beta-hexosaminidase B | Degrades globoside; Sandhoff disease model |
How Is galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity Regulated?
The activity of GO:0047273 is likely regulated by substrate availability, enzyme expression levels, and post-translational modifications, similar to other glycosyltransferases. For instance, GALNT2 expression is modulated in cancer and metabolic tissues, and GALNT3 is regulated by Runx2 in bone. However, specific regulatory mechanisms for the globoside synthase step remain to be fully defined.
galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALNT2 | Glioma stemness; lung cancer oncogenesis | Knockout and overexpression in glioma and NSCLC cell lines |
| GALNT3 | Osteoid mineralization; FGF23 regulation | Knockout in osteoblast-like cells; point mutation for catalytic activity |
| GALNT7 | Immunotherapy resistance in NSCLC | Knockout and overexpression in NSCLC cells; ferroptosis assays |
| B3GALNT1 | Globoside biosynthesis; potential cancer and lysosomal storage links | Knockout and knock-in in cell lines; glycolipid profiling |
| GALNT2 | Hypoglycemia counterregulation | Neuron-specific knockout in mice; metabolic tracing |
Cancer and Metastasis
Altered O-GalNAc glycosylation, including globo-series glycosphingolipid synthesis, is implicated in cancer progression. GALNT2 sustains glioma stem cells by promoting CD44 expression, and acts as an oncogenic driver in non-small cell lung cancer. O-GalNAc glycosylation can activate MBL-mediated complement and coagulation cascades to drive organotropic metastasis. GALNT7-dependent ferroptosis suppression contributes to immunotherapy resistance in NSCLC. These findings suggest that enzymes in the globo-series pathway, including GO:0047273, may influence tumor behavior.
Metabolic and Bone Disorders
GALNT3 regulates FGF23 expression and osteoid mineralization by stabilizing FGF23. Indoxyl sulfate induces left ventricular hypertrophy via AhR-FGF23-FGFR4 signaling, linking glycosylation-related pathways to cardiovascular complications. GALNT2 neurons in the ventromedial hypothalamus counterregulate hypoglycemia via a brain-liver neurocircuit, highlighting metabolic roles.
Infectious Disease and Immune Regulation
Sequential glycosylations at the multibasic cleavage site of SARS-CoV-2 spike protein regulate viral activity, demonstrating the importance of glycosylation in viral pathogenesis. O-GalNAc glycosylation activates complement and coagulation cascades, which may affect immune responses. These studies underscore the broad relevance of glycosylation enzymes to infectious and immune diseases.
From galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of B3GALNT1 abolish globoside synthesis? | CRISPR knockout in HEK293 or cancer cell lines; lipidomics |
| Which residues are essential for catalytic activity? | Point mutation of predicted catalytic residues; biochemical assay |
| Can a tagged enzyme be used for localization studies? | Knock-in of FLAG or GFP tag at endogenous locus; imaging |
| Does overexpression of GALNT2 increase globoside levels? | Overexpression in glioma or lung cancer cells; flow cytometry |
| What is the role of GALNT7 in ferroptosis? | Knockout and overexpression in NSCLC; ferroptosis inducers |
| How does GALNT3 affect FGF23 stability? | Knockout and point mutation in osteoblast models; Western blot |
How to Study the galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Transfer of GalNAc to Gb3 | Biochemical characterization of GO:0047273 |
| Lipidomics (LC-MS) | Glycosphingolipid levels | Profiling Gb3, Gb4 in knockout cells |
| CRISPR knockout screen | Gene essentiality for glycosylation | Identifying regulators of globo-series pathway |
| Flow cytometry | Cell surface globoside expression | Phenotyping cancer cells |
| Western blot | Protein expression of GALNTs | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Tagged enzyme knock-in |
| RNA-seq | Transcriptional changes | Pathway analysis after perturbation |
| Proteomics | Protein glycosylation changes | Global O-GalNAc profiling |
Biochemical Enzyme Assays
Enzyme activity can be measured using radiolabeled UDP-GalNAc and Gb3 as substrates, followed by product separation via thin-layer chromatography or mass spectrometry. These assays directly quantify GO:0047273 activity.
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes required for globoside synthesis or glycosylation-dependent phenotypes. For example, screens in cancer cells can reveal vulnerabilities linked to GALNT family members.
Glycolipid Profiling by Mass Spectrometry
Mass spectrometry-based lipidomics enables comprehensive profiling of glycosphingolipids, including Gb3 and Gb4, to assess the impact of genetic perturbations on GO:0047273.
Antibody-Based Detection and Imaging
Antibodies against globoside (Gb4) or tagged enzymes can be used in flow cytometry, immunofluorescence, or immunohistochemistry to study expression and localization.
How CRISPR Can Be Used to Study GO:0047273 galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity
Knockout
CRISPR knockout of B3GALNT1 or related GALNT genes can abolish GO:0047273 activity, leading to loss of globoside and accumulation of Gb3. This model is useful for studying downstream effects on cell signaling, adhesion, and immune recognition.
Point Mutation
Introducing point mutations in the catalytic domain of B3GALNT1 can dissect substrate binding and catalytic residues. Such models help distinguish enzyme activity from structural roles.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous locus allows real-time tracking of enzyme localization and interaction partners without overexpression artifacts.
Overexpression
Overexpression of GALNT2, GALNT7, or B3GALNT1 in cancer cell lines can drive increased glycosylation, promoting stemness, metastasis, or therapy resistance. These models are valuable for target validation.
How EDITGENE Supports galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity Research
Researchers studying galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosphingolipid metabolism, cancer progression, or immune regulation. EDITGENE provides comprehensive CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity research.
Frequently Asked Questions About galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity
What is GO:0047273?
GO:0047273 is the Gene Ontology molecular function term for galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity, which catalyzes the transfer of GalNAc to globotriaosylceramide to form globoside.
What reaction does galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase catalyze?
It transfers N-acetyl-D-galactosamine from UDP-N-acetyl-D-galactosamine to alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide, producing globoside and UDP.
What genes are involved in galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity?
The primary gene is B3GALNT1, which encodes globoside synthase. Related genes include other GALNT family members and glycosphingolipid pathway enzymes.
What diseases are associated with this activity?
Altered globo-series glycosphingolipid synthesis is linked to cancer progression, metastasis, and immune regulation, as well as lysosomal storage disorders.
How can I study galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity?
Biochemical enzyme assays, lipidomics, CRISPR knockout models, and overexpression studies are commonly used.
What is globoside synthase?
Globoside synthase is a synonym for GO:0047273, referring to the enzyme that synthesizes globoside (Gb4) from Gb3.
Is galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity involved in cancer?
Yes, globo-series glycosphingolipids and related O-GalNAc glycosylation are implicated in cancer stemness, metastasis, and immunotherapy resistance.
What cell models are available for studying this activity?
CRISPR knockout, point mutation, knock-in, and overexpression cell models can be generated in cancer or metabolic cell lines.
How does EDITGENE support research on this activity?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for glycosylation genes.
What is the difference between GO:0047273 and other glycosyltransferase activities?
GO:0047273 specifically catalyzes the beta-1,3-GalNAc transfer to Gb3, whereas other glycosyltransferases act on different substrates or form different linkages.
Conclusion
GO:0047273, galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity, is a key enzymatic step in globo-series glycosphingolipid biosynthesis. Its product, globoside, and related glycosphingolipids play critical roles in cell signaling, cancer progression, and immune regulation. Understanding this activity through biochemical assays and CRISPR models can reveal new therapeutic targets. EDITGENE offers comprehensive services to accelerate research on this and related glycosylation pathways.
References
- 1. Jiang Q et al.. 2024. Runx2 Regulates Galnt3 and Fgf23 Expressions and Galnt3 Decelerates Osteoid Mineralization by Stabilizing Fgf23.. Int J Mol Sci 25(4) PMID: 38396954
- 2. Wang J et al.. 2025. Galnt2 neurons in the ventromedial hypothalamus counterregulate hypoglycemia via a brain-liver neurocircuit.. Cell Metab 37(11):2264-2279.e10 PMID: 41092902
- 3. Liu Y et al.. 2023. GALNT2 sustains glioma stem cells by promoting CD44 expression.. Aging (Albany NY) 15(6):2208-2220 PMID: 37000153
- 4. Chen X et al.. 2025. O-GalNAc Glycosylation Activates MBL-Mediated Complement and Coagulation Cascades to Drive Organotropic Metastasis.. Adv Sci (Weinh) 12(32):e04809 PMID: 40492591
- 5. Kishimoto H et al.. 2023. Indoxyl sulfate induces left ventricular hypertrophy via the AhR-FGF23-FGFR4 signaling pathway.. Front Cardiovasc Med 10:990422 PMID: 36895836
- 6. Gan J et al.. 2026. Single-Cell Reveal GALNT7-Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non-Small Cell Lung Cancer.. Adv Sci (Weinh) 13(50):e76082 PMID: 42318657
- 7. Hu Q et al.. 2022. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.. Cell Mol Biol Lett 27(1):71 PMID: 36058918
- 8. Wang S et al.. 2024. Sequential glycosylations at the multibasic cleavage site of SARS-CoV-2 spike protein regulate viral activity.. Nat Commun 15(1):4162 PMID: 38755139
